Zimmer Biomet Holdings, Inc.
Zimmer Biomet Holdings, Inc. is classed by the SEC under Orthopedic, Prosthetic & Surgical Appliances & Supplies (industry code 3842), based in Warsaw, IN. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $8.2 billion and a profit of $705 million (its filed statements).
vs its business-model standard
Three tenses, nine metrics. Unseen metrics stay unseen; the grade never fakes a number. Proxy era: provisional values, marked. Weighed as a product business: prior from its industry code (SEC 3842, Orthopedic, Prosthetic & Surgical Appliances & Supplies); the filing read can change it. All three tenses have at least two readings, so the archetype blend applies as printed.
The grade, in three tenses
Headline 6.1 out of ten, 9 of 9 metrics filed: past 6.6 out of ten, present 6.3 out of ten, future 5.5 out of ten. The past asks what it actually did, the present what it is doing right now, the future what it is set up to do next.
The nine metrics
- Surviving crises (past): 7.8 out of ten. No warning events in its filings since 2017. 78th percentile among 29 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Track record (past): 5.3 out of ten. +0.8% a year over 10 filed years; profitable in 8 of 10. 53rd percentile among 25 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Shareholder treatment (past): 7.5 out of ten. Share count shrank 1.9% a year. 55% of cash flow returned. Insiders: 6 sales, 0 purchases. 75th percentile among 12 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Financial health (present): 5.8 out of ten. ROE 6%: 6¢ of profit per shareholder dollar. Leverage 45%: owes 45¢ per asset dollar. 58th percentile among 27 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Industry position (present): 7.3 out of ten. top 27% of 26 in its family; net margin 8.6%. 73rd percentile among 26 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Leadership (present): 5.7 out of ten. top 43% of 16 in its family for leadership; chief executive since 2023. 57th percentile among 16 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-09).
- Room to expand (future): 5.5 out of ten. top 46% of 25 in its family for room to expand. 54th percentile among 25 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Growth drivers (future): 5.8 out of ten. top 42% of 25 in its family for growth drivers. 58th percentile among 25 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
- Expectations vs reality (future): 5.1 out of ten. top 49% of 23 in its family for expectations against reality. 51st percentile among 23 sector filers. A production reading, recomputed from the filings on every data build (read from EDGAR 2026-10-12).
The filing record
Newest annual report: Form 10-K filed 2026-02-20 for the period ended 2025-12-31 (on EDGAR). Newest quarterly report: Form 10-Q filed 2026-08-05 for the period ended 2026-06-30 (on EDGAR). Newest results release: Form 8-K filed 2026-08-05 (on EDGAR). Newest filing: Form 4, 2026-10-05. Filings on record since 2001. Read from EDGAR 2026-10-12.
Where the revenue comes from
Product and service lines in fiscal 2025: Knees 40%, SET 26%, Hips 25%, Technology and Data Bone Cement and Surgical 8%. By geography: United States 58%, Outside the United States 42%. As tagged in its annual report (Form 10-K, filed 2026-02-20).
Who runs it
Tornos, Ivan (Chairman, President and CEO); Campbell, Gary Craig (President, Americas); Phipps, Chad F (Senior Vice President, Chief Legal & Corporate Affairs Officer and Secretary); Desai, Chintan (President, APAC); Noor, Jehanzeb (Senior Vice President, Chief Strategy, Innovation & Business Development Officer); Yi, Sang (Group President, Asia Pacific); Upadhyay, Suketu (Exec VP, CFO); Thornal, Kevin R (Grp Pres-Global Business); Stellato, Paul A (VP, Controller, CAO); Winkler, Lori (SVP and CHRO); and 10 more. 20 officers and directors have filed their own trades in the last fifteen months, names and titles as filed with the SEC, through 2026-10-05.
This file: Overview · Past · Present · Future · Filings · every company on file
Every stock is a company. We grade the company behind the stock. CrossAssetData is a company research product: no investment advice, no price targets, no price predictions; every claim carries its source, and unseen means unseen. The full file draws when the page's script runs: the essentials, the balance sheet, the estimators, the trend, and every filing of the last ten years.